Good Pharmacovigilance Practice (GVP) Trainings
GxP Cellators provides specialized Good Pharmacovigilance Practice (GVP) training and implementation programs for pharmaceutical, biotechnology, and medical device organizations. Our programs align with global regulatory requirements, including those from the European Medicines Agency (EMA GVP framework), the US FDA, Health Canada, the Medicines and Healthcare products Regulatory Agency (MHRA), and the Therapeutic Goods Administration (TGA).
We offer flexible delivery options, including on site instructor led programs, live virtual sessions, and blended learning formats. These are supported by practical implementation assistance to enhance pharmacovigilance compliance and inspection readiness.
Applicable Standards and Regulations:
- EU: GVP Modules I through XVI, EudraLex Volume 9 (pharmacovigilance), Regulation (EC) No 726/2004, Directive 2001/83/EC
- US FDA: 21 CFR Part 312 (IND safety reporting), 21 CFR Part 314 (NDA safety reporting), FDA Guidance on Good Pharmacovigilance Practices
- Health Canada: Pharmacovigilance requirements under the Food and Drugs Act, Protecting Canadians from Unsafe Drugs Act (Vanessa's Law)
- Other: MHRA Good Pharmacovigilance Practice Guide, TGA Pharmacovigilance Responsibilities of Medicine Sponsors, WHO Pharmacovigilance Guidelines
- ICH: E2A (clinical safety data management), E2B (electronic transmission of safety data), E2C (periodic safety update reports), E2D (post approval safety data management), E2E (pharmacovigilance planning)
- ISO: 9001 (quality management)
Core Training and Capability Development Areas
Our GVP training curriculum focuses on the systematic detection, assessment, understanding, and prevention of adverse effects. Each module addresses specific regulatory expectations and real world pharmacovigilance challenges.
AREA 01 / 04
GVP Principles and Global Regulatory Expectations
- 01
Core GVP Requirements and Lifecycle Application
Pharmacovigilance is not limited to post marketing reporting. This module covers the fundamental requirements of GVP including adverse event collection, signal detection, risk assessment, and risk minimization throughout the product lifecycle. Participants learn how GVP principles apply from clinical development through post marketing surveillance and how pharmacovigilance activities impact patient safety and product labeling.
- 02
Roles and Responsibilities Within the Pharmacovigilance System
Pharmacovigilance involves multiple parties including marketing authorization holders, sponsors, contract research organizations, and third party service providers. This training clarifies the regulatory responsibilities of each party under global GVP frameworks. Participants learn how to define roles in pharmacovigilance agreements, how to establish clear lines of communication, and how to ensure accountability when safety activities are outsourced.
- 03
Risk Based Pharmacovigilance Strategies
Not all products carry the same safety risk. This module teaches risk assessment methodologies specifically for pharmacovigilance activities. Participants learn to evaluate product safety profiles, identify potential signals, allocate pharmacovigilance resources proportionally to risk levels, and document risk based decisions for regulatory inspection.
Applicable Standards: EU GVP Modules I through XVI, US FDA 21 CFR Part 312 and 314, Health Canada Pharmacovigilance requirements, MHRA Good Pharmacovigilance Practice Guide, TGA Pharmacovigilance Responsibilities, WHO Pharmacovigilance Guidelines, ICH E2E.
AREA 02 / 04
Adverse Event Reporting and Case Management
- 01
Individual Case Safety Report (ICSR) Processing
Accurate and timely ICSR processing is the foundation of pharmacovigilance. This module covers the complete ICSR lifecycle from initial receipt through triage, data entry, medical review, quality review, and submission. Participants learn to identify reportable cases, assess seriousness and expectedness, and apply regulatory reporting timelines.
- 02
Expedited Reporting Requirements
Regulatory authorities require expedited reporting of serious unexpected suspected adverse reactions (SUSARs) and other safety information. This training covers the criteria for expedited reporting, the timelines for submission to different regulatory authorities, and the documentation requirements for expedited reports. Participants practice preparing expedited reports for FDA, EMA, and Health Canada.
- 03
Electronic Submission and E2B Standards
Electronic submission of safety data is now mandatory in most jurisdictions. This module covers the E2B standard formats for electronic transmission of ICSRs, the regulatory gateways for submission (e.g., FDA ESG, EMA EudraVigilance, Health Canada), and the technical requirements for successful electronic submission. Participants learn to troubleshoot common submission errors.
Applicable Standards: ICH E2A, E2B(R2) and E2B(R3), EU GVP Module VI (management and reporting of adverse reactions), US FDA 21 CFR Part 312 and 314, Health Canada Pharmacovigilance requirements, MHRA Good Pharmacovigilance Practice Guide.
AREA 03 / 04
Signal Detection and Risk Management
- 01
Signal Detection Methodologies
Signal detection is the process of identifying new safety concerns from available data. This module covers both qualitative and quantitative signal detection methods including individual case review, literature screening, database mining, and statistical disproportionality analysis. Participants learn how to validate signals, assess clinical significance, and document signal evaluation.
- 02
Risk Management Plans (RMP) Development
Risk Management Plans are required for products with significant safety concerns. This training covers the structure and content of EU RMPs and FDA Risk Evaluation and Mitigation Strategies (REMS). Participants learn to develop safety specifications, plan pharmacovigilance activities, and design risk minimization measures. The module includes practical exercises on RMP development.
- 03
Periodic Safety Reports and Benefit Risk Evaluation
Periodic reports are required to provide ongoing benefit risk assessment. This module covers the preparation of Periodic Safety Update Reports (PSURs), Periodic Benefit Risk Evaluation Reports (PBRERs), and Annual Summary Reports (ASRs). Participants learn to analyze cumulative safety data, evaluate benefit risk balance, and propose regulatory actions.
Applicable Standards: EU GVP Module V (risk management systems), Module VII (periodic safety update reports), Module VIII (post authorization safety studies), US FDA REMS guidance, ICH E2C(R2), ICH E2E, Health Canada Pharmacovigilance requirements.
AREA 04 / 04
Pharmacovigilance System and Inspection Readiness
- 01
Pharmacovigilance System Master File (PSMF)
The PSMF is a comprehensive document describing the pharmacovigilance system. This module covers the structure and content requirements for the PSMF, including the Quality Management System, personnel, procedures, and databases. Participants learn how to maintain the PSMF, update it for changes, and prepare it for inspection.
- 02
Pharmacovigilance Audits and Inspections
Regulatory authorities conduct pharmacovigilance inspections to verify compliance. This training prepares participants for inspections including how to prepare staff for regulator interviews, how to organize records for rapid retrieval, how to conduct mock inspections, and how to respond to inspection findings. Participants learn from real examples of pharmacovigilance inspection findings and successful remediation responses.
- 03
Quality Management System for Pharmacovigilance
A robust QMS is essential for pharmacovigilance compliance. This module covers the design and implementation of pharmacovigilance QMS elements including standard operating procedures, training programs, deviation management, CAPA management, and change control. Participants learn to apply ICH Q9 and Q10 principles to pharmacovigilance activities.
Applicable Standards: EU GVP Module I (pharmacovigilance systems and their quality systems), Module II (pharmacovigilance system master file), Module III (pharmacovigilance inspections), Module IV (pharmacovigilance audits), ICH Q9, ICH Q10, MHRA Good Pharmacovigilance Practice Guide.
Beyond Training: Strengthening Pharmacovigilance Capability
GxP Cellators combines regulatory expertise with practical implementation. We help organizations build inspection ready pharmacovigilance systems through integrated consulting services that work alongside our training programs.
- 01
GVP Gap Assessments and Compliance Roadmaps
We conduct gap assessments comparing your current pharmacovigilance practices against GVP requirements from EMA, FDA, Health Canada, MHRA, and TGA. Each assessment includes document review, system evaluation, staff interviews, and data analysis. The output is a detailed compliance roadmap with prioritized actions, realistic timelines, and responsible parties.
- 02
SOP Development for Pharmacovigilance
Clear Standard Operating Procedures are essential for GVP compliance. We help clients develop new pharmacovigilance SOPs or remediate existing documents. Typical SOPs include adverse event reporting, signal detection, risk management, PSUR preparation, PSMF maintenance, and pharmacovigilance audit. Each SOP is written for clarity and practical use by pharmacovigilance staff.
- 03
Pharmacovigilance System Implementation
We provide hands on support for pharmacovigilance system implementation including database selection, workflow design, quality control processes, and regulatory submission setup. Our team can lead the implementation or train your staff to execute independently.
- 04
Continuous Compliance Mentoring
Pharmacovigilance compliance requires ongoing attention. GxP Cellators offers retainer based mentoring where our pharmacovigilance experts meet regularly with your safety, quality, and regulatory teams. We review recent safety data, audit findings, and regulatory trends. We coach investigators on signal evaluation and risk assessment. We update training materials based on emerging GVP regulatory trends. This mentoring builds lasting pharmacovigilance compliance capability.
Applicable Standards: EU GVP Modules I through XVI, US FDA 21 CFR Part 312 and 314, Health Canada Pharmacovigilance requirements, MHRA Good Pharmacovigilance Practice Guide, TGA Pharmacovigilance Responsibilities, ICH E2A, E2B, E2C, E2D, E2E, WHO Pharmacovigilance Guidelines.
GxP Cellators. Safeguarding Patient Safety Through Pharmacovigilance Excellence.
Reach Out to Us
For more details or to discuss your project requirements, please reach out to us. Your query will be handled with complete confidentiality and we will ensure a prompt response.
Expert GxP Compliance Consultants for Life Sciences – GMP, GLP, GCP, GDP and ISO services for pharmaceutical, biopharmaceutical and medical device companies.
Our Services
Our Presence
- Saskatchewan, Canada
- Calgary, Canada
- Toronto, Canada
- North Carolina, USA
- Frankfurt, Germany
- Indiana, USA
© 2026, GxP Cellators. All Rights Reserved.
